Grünenthal Limited
TOR Building
St Cloud Way
Maidenhead SL6 8BN
Phone: +44 0800 254 5540

For Medical Information, Reporting Safety and Quality Related Issues see here

... About us

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 29 countries with affiliates in Europe, Latin America and the USA. Our products are sold in more than 100 countries and we employ around 4,700 employees worldwide.

... Company Overview

Although firmly rooted in Germany, today we are very much a growing global business.

... History

At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact on society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.

... Responsibility

Although firmly rooted in Germany, today we’re very much a growing global business, represented in 27 countries and maintaining production sites in five.

... Global Capabilities

We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.

... Initiatives

... Requests for Funding

Working towards a world free of pain

Our company has a clear vision of a world free of pain and we maintain a strong focus on this vision in everything we do in our research and development activities.

As a global leader in pain research and development, we are passionate about exploring innovative treatment options that have the potential to meaningfully improve the lives of patients around the world. Every day, Grünenthal’s scientists use their deep expertise to reimagine the future of pain management.

Executing our therapeutic area strategy, we focus on four key areas for creating life-changing innovations: peripheral neuropathic pain, chronic post-surgical pain, chronic lower back pain, and osteoarthritis. We take a holistic approach to pursuing breakthrough treatments for these pain conditions – and explore all possible technologies and modalities. This enables us to pursue our priorities with a solution-agnostic mindset. We focus our in-house capabilities on critical and differentiating areas such as target identification, with a strong emphasis on human and clinical validation, as well as translational science and disease understanding. While focusing on these specific critical success factors, we are able to cover every step in the development of an innovative medicine. At the same time, we are committed to entering into strategic partnerships with innovative players from across industry and academia who share our passion for shaping the field and fostering the development of meaningful therapies.

“We are committed to developing innovative treatment options for patients with pain. Together with my team, I strive to bring the best science forward.”

Uli Brödl, MD,

Head of R&D, Chief Scientific Officer

Alongside our focus on these four indications, we are also seeking to join forces with partners to develop new therapeutic solutions for fibromyalgia, complex regional pain syndrome, migraine and peri-surgical pain.

You can find more information about our strategy, global presence, partnerships and projects on this section of our website. And you can also find detailed descriptions of our focus areas below.